Tag Archives: biotechnology news

Excerpts From Amicus Briefs Supporting Prometheus

Posted on November 11, 2011 by Warren Woessner

This intriguing compilation “Excerpts From 15 AMICI Briefs Supporting Respondent Prometheus: Mayo Collaborative Services v. Prometheus Laboratories, Inc.,” was sent to me by Mark Corallo of Corallo Media Strategies, Inc., Alexandria, VA. UNH Law used to be Franklin Pierce Law … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

EPO Ruling On Inventiveness Of Drug Polymorphs

Posted on November 5, 2011 by Warren Woessner

Thank you to Dr. Stefan Danner, a German and European Patent Attorney at DHS Patentanwaltsgesellschaft mbH in Munich for letting us post the current issue of the biotech IP newsletter dealing with the recent EPO decision concerning the patentability of … Continue reading →

Posted in EP and UK Practice | Tagged , , , , , , , , , , | Leave a comment

Obviousness = Equivalence? Saint-Gobain v. Siemens

Posted on October 14, 2011 by Warren Woessner

Saint-Gobain Ceramics (“S-G”) has asked the Supreme Court to review the Fed. Cir. panel below, 647 F.3d 1373 (Fed. Cir. 2011) in which the panel decision refused to reverse a district court decision that instructed the jury that it could … Continue reading →

Posted in Doctrine of Equivalents | Tagged , , , , , , , , , , , , , , | 1 Comment

Obviousness Objections Based On Combinations Of References – Consistent Warnings From The CAFC

Posted on August 31, 2011 by Warren Woessner

By Paul Cole, Professor of Intellectual Property Law, Bournemouth University; Lucas & Co, Warlingham, UK Those prosecuting patent applications before the USPTO, the EPO and other examining patent offices confront on a daily basis objections of the kind: “A is known … Continue reading →

Posted in Obviousness | Tagged , , , , , , , , , , , , , , | Leave a comment